Company Quick10K Filing
Luckwel Pharmaceuticals
10-Q 2019-12-31 Filed 2020-02-13
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-K 2019-03-31 Filed 2019-07-02
10-Q 2018-12-31 Filed 2019-02-14
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-K 2018-03-31 Filed 2018-07-16
10-Q 2017-12-31 Filed 2018-02-12
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-10
10-K 2017-03-31 Filed 2017-06-27
10-Q 2016-12-31 Filed 2017-02-03
10-Q 2016-09-30 Filed 2016-11-10
10-Q 2016-06-30 Filed 2016-08-11
10-K 2016-02-29 Filed 2016-05-02
10-Q 2015-11-30 Filed 2016-01-11
10-Q 2015-08-31 Filed 2015-10-15
10-Q 2015-05-31 Filed 2015-07-09
10-K 2015-02-28 Filed 2015-06-01
10-Q 2014-11-30 Filed 2015-01-14
10-Q 2014-08-31 Filed 2014-09-19
10-Q 2014-05-31 Filed 2014-08-06
8-K 2019-06-12 Accountant, Exhibits
8-K 2019-03-14 Enter Agreement, Exhibits
8-K 2018-10-11 Enter Agreement, Exhibits
8-K 2018-06-20 Enter Agreement, Exhibits
8-K 2018-05-07
8-K 2018-04-13 Amend Bylaw, Exhibits

Luckwel Pharmaceuticals Financials

LWEL Metrics, Comps, Filings

Quarterly | Annual

Business

We were incorporated on January 2, 2013 under the laws of the State of Nevada. Our principal executive offices are located at 303 Wyman St Suite 300, Waltham, MA 02451. Our telephone number is 781-728-0007. Our fiscal year end is March 31.

On March 30, 2017, our name was changed from Luckycom Inc. to Luckycom Pharmaceuticals Inc. and again on April 11, 2018, our name was changed to Luckwel Pharmaceuticals Inc. In connection with the most recent name change, on April 13, 2018, our common stock began trading on the OTC Pink under its new ticker symbol “LWEL” and ceased trading under the ticker symbol “LCOM”. Also on April 13, 2018, we increased the number of our authorized shares of common stock from 100,000,000 to 200,000,000.

We are presently still a shell company and have not begun operations. We have no source of revenue and need additional cash resources to maintain the operations. Our ability to continue as a going concern is dependent on our ability to raise additional capital or obtain necessary debt financing. We are presently dependent on our Chief Executive Officer, Mr. Kingrich Lee to either provide us funding for its daily operation and expenses, including professional fee and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Taronis Technologies (TRNX) 45% -0.0 -41% 47,761 11,488 16,133 7,338 -19,801 -18,200 124
CCO Holdings (CCOH) 0% 44.2 1% 143,810,000 66,912,000 33,997,000 0 1,602,000 1,688,000 74,609,000
Mirenco (MREO) 30% -1.0 -58% 499 1,846 211 64 -290 -239 249
Global Diversified Futures Fund (GDFF) -4.4 5% 14,501 3,605 0 0 722 722 -3,164
Worlds (WORLD) 1.4 -52% 1,933 3,222 0 0 -1,002 -813 -1,159
Skinvisible (SKVI) 78% -3.9 -613% 208 2,788 32 25 -1,275 -530 2,050
Wytec (WYTC) 33% 0.4 -123% 1,625 1,701 260 86 -1,997 -1,870 -735
AB International Group (ABQQ) 59% 8.9 -4% 4,576 345 434 255 -176 -176 -1,565
Valero Energy Partners (VLP) 39% 2.3 16% 1,619,609 1,320,906 546,427 211,259 264,095 362,274 837,751
LED Lighting (LEDL) 0.0 -2,507% 4 12 0 0 -93 -93 -4
Luckwel Pharmaceuticals (LWEL) 0.0 -2,833% 17 1,061 0 0 -495 -495 -4
World Health Energy Holdings (WHEN) -0.0 346% 24 376 0 0 82 82 -0
Oncor Electric Delivery (C311) 0% 5,753.8 2% 26,744,000 16,433,000 4,263,000 0 637,000 1,560,000 8,975,990,000
Ameri Holdings (AMHI) 21% 0.6 -12% 26,656 13,409 30,850 6,422 -3,075 -853 -500
eWellness Healthcare (EWLL) 0.2 -387% 1,196 5,783 0 0 -4,624 -4,616 -781
Dominion Minerals (DMNM) 0.0 -7,862% 2 6,912 0 0 -156 -156 -2
TRxADE Group (TRXD) 62% -10.1 5% 5,855 1,964 7,657 4,784 269 331 -3,359
Palayan Resources (PALA) 0.0 -4,194% 1 184 0 0 -43 -42 -1
Frelii (FRLI) 76% 0.0 -301% 1,682 533 44 33 -5,058 -5,049 -12
Mullan Agritech (MHDG) 41% 2.4 9% 25,773 15,810 9,677 3,968 2,266 3,563 8,415

Balance Sheet ($'000)2014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash732593484022123811714416081292932091301934304326724
Accounts Receivable
Inventory
PP&E
Assets103481095743361238117144160815233624814519343143278617
Accounts Payable
Long-Term Debt
Liabilities231238381393441582433204215265395851061301484245808558191,0181,061
Stockholders' Equity-52684-60-55-184-34225014215-129-390-549-812-792-932-1,044
Income Statement ($'000)2014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue
Cost of Revenue
Gross Profit
R&D
SG&A11011312999158-108123144220257263-20141111
Tax000000000000000000000
Net Income-56-63-81-64-62-140-88-130-110-113-129-159-157-109-127-144-220-159-26320-141-111
Cash Flow ($'000)2014-05-312014-08-312014-11-302015-02-282015-05-312015-08-312015-11-302016-02-292016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-58-56-74-57-56-68-87-133-92-97-118-153-178-103-104-131-213-0-282-108-62
Cash Investing0000000
Cash Financing36814212482491041115011339101441192420229-4265155-6